Want to see HK:1466 full AI Analyst Report?
Top Page
Affluent Partners Holdings
(1466)
Select Model
Select Model
Rating:54Neutral
Price Target:
HK$1.00
▲(29.87% Upside)
Action:Reiterated
Date:09/08/26
The score is held back primarily by weak financial performance: a steep profitability decline and ongoing negative operating/free cash flow outweigh the benefit of improved leverage. Technicals provide support with clear price strength and positive momentum indicators, but near-overbought readings temper the upside. Valuation is not supportive because the negative P/E reflects losses and there is no dividend yield data.
Positive Factors
Debt Reduction
The substantial reduction in leverage strengthens the capital structure and lowers the balance-sheet burden relative to equity. This gives Affluent Partners greater resilience over the next several quarters, although the benefit is partly offset by continuing losses and weak cash generation.
Negative Factors
Revenue Decline
The sharp revenue contraction indicates weakened demand, reduced business scale, or execution pressure in the latest period. Sustained top-line deterioration can impair operating leverage, reduce resources available for investment, and make a durable earnings recovery more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt Reduction
The substantial reduction in leverage strengthens the capital structure and lowers the balance-sheet burden relative to equity. This gives Affluent Partners greater resilience over the next several quarters, although the benefit is partly offset by continuing losses and weak cash generation.
Read all positive factors
Affluent Partners Holdings (1466) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.17B
Dividend YieldN/A
Average Volume (3M)1.20M
Price to Earnings (P/E)―
Beta (1Y)-0.55
Revenue Growth-34.12%
EPS Growth-2893.33%
CountryHK
Employees84
SectorConsumer Cyclical
Sector Strength84
IndustryLuxury Goods
Share Statistics
EPS (TTM)-0.06
Shares Outstanding932,254,100
10 Day Avg. Volume1,941,120
30 Day Avg. Volume1,200,406
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.69
Price to Sales (P/S)5.57
P/FCF Ratio-22.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Affluent Partners Holdings Business Overview & Revenue Model
Company Description
Affluent Partners Holdings Limited, an investment holding entity founded in 2014 and situated in Central, Hong Kong, conducts various operations. Its core business involves the full lifecycle of pearls and jewelry products, including their acquisi...
Affluent Partners Holdings Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
63
Positive
Cash Flow
28
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 89.30M | 135.56M | 53.68M | 86.88M | 62.65M |
| Gross Profit | 6.67M | 41.99M | 18.10M | 7.83M | 10.99M |
| EBITDA | -38.37M | 6.26M | -6.32M | 11.13M | -9.73M |
| Net Income | -37.87M | -316.00K | -7.45M | 8.73M | -15.46M |
Balance Sheet | |||||
| Total Assets | 264.44M | 290.17M | 196.80M | 99.85M | 82.11M |
| Cash, Cash Equivalents and Short-Term Investments | 43.11M | 47.77M | 37.88M | 41.26M | 23.59M |
| Total Debt | 28.41M | 99.93M | 51.19M | 2.76M | 31.84M |
| Total Liabilities | 72.18M | 134.30M | 84.01M | 21.51M | 46.24M |
| Stockholders Equity | 185.19M | 139.28M | 96.31M | 78.34M | 35.87M |
Cash Flow | |||||
| Free Cash Flow | -22.56M | -32.97M | -6.64M | -21.55M | 1.06M |
| Operating Cash Flow | -7.16M | -30.53M | -6.46M | -21.52M | 1.11M |
| Investing Cash Flow | -20.39M | -846.00K | 4.74M | 35.30M | -60.00K |
| Financing Cash Flow | 22.50M | 41.41M | 819.00K | 3.70M | -1.72M |
Affluent Partners Holdings Technical Analysis
Positive
0.77
Price Trends
1.01
Positive
0.81
Positive
0.69
Positive
Market Momentum
0.06
Negative
70.09
Negative
80.12
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1466, the sentiment is Positive. The current price of 0.77 is below the 20-day moving average (MA) of 0.99, below the 50-day MA of 1.01, and above the 200-day MA of 0.69, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 70.09 is Negative, neither overbought nor oversold. The STOCH value of 80.12 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1466.
Affluent Partners Holdings Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | HK$2.18B | 3.79 | 9.96% | 6.80% | 8.83% | 109.28% | |
77 Outperform | HK$1.63B | 9.16 | 9.99% | 6.11% | -0.78% | -10.18% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
61 Neutral | HK$1.45B | -14.04 | -2.86% | 12.82% | -21.99% | -138.89% | |
54 Neutral | HK$1.17B | -22.64 | -23.23% | ― | -34.12% | -2893.33% | |
47 Neutral | HK$519.25M | -3.72 | -3.03% | 3.75% | -4.85% | 60.69% | |
41 Neutral | HK$603.43M | -16.42 | -68.91% | 3.10% | -8.88% | 42.89% |
* Consumer Cyclical Sector Average
HK:1466
Affluent Partners Holdings
1.23
0.73
146.00%
HK:0256
Citychamp Watch & Jewellery Group
0.11
-0.12
-52.81%
HK:0887
Emperor Watch & Jewellery
0.29
0.02
5.84%
HK:3389
Hengdeli Holdings
0.30
0.17
130.47%
HK:0398
Oriental Watch Holdings
3.41
0.22
6.86%
HK:1856
Ernest Borel Holdings Ltd
1.68
0.13
8.39%
Affluent Partners Holdings Corporate Events
Baijin Life Science Sets 2026 AGM to Approve Accounts, Board Mandates and Share Issuance Authority
Aug 20, 2026
Baijin Life Science Holdings has convened its 2026 annual general meeting for mid-September in Hong Kong, where shareholders will review the audited financial statements for the year ended 31 March 2026 and consider the re-election of four retirin...
Baijin Life Science Swings to Deep Annual Loss as Revenue Falls
Jun 30, 2026
Baijin Life Science Holdings reported a sharp decline in revenue to HK$89.3 million for the year ended 31 March 2026, down from HK$135.6 million a year earlier, with gross profit contracting significantly to HK$6.7 million. Despite higher other ga...
Baijin Life Science Warns of Sharply Wider Annual Loss
Jun 29, 2026
Baijin Life Science Holdings has issued a profit warning, indicating it expects to post a loss of not more than HK$43.0 million for the year ended 31 March 2026, a sharp deterioration from the approximately HK$0.1 million loss recorded a year earl...
Baijin Life Science says China Water liquidation has no impact on its operations
Jun 18, 2026
Baijin Life Science Holdings has disclosed an update on director information after a Hong Kong court ordered the winding up of China Water Industry Group, where Baijin’s non-executive director Zhu Yongjun serves as chairman and executive dir...
Baijin Life Science Sets Board Meeting to Approve 2026 Results and Mull Final Dividend
Jun 17, 2026
Baijin Life Science Holdings has scheduled a board meeting for 30 June 2026 to approve the annual results for the year ended 31 March 2026. The board will also consider recommending a final dividend, a decision that could affect shareholder return...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.